American Center for Cures and BlueCloudX announced a strategic collaboration aimed at accelerating the development of cures for major diseases while dramatically reducing the time, cost, and complexity of clinical research.
A phase III clinical trial will soon begin testing the evidence collected thus far that points to a stunning prospect: the COVID-19 vaccine—a widely accessible mRNA vaccine already on the market—could make checkpoint inhibitors work better for lung cancer and melanoma patients.
